$84,091,682
SHINE WAS FOUNDED IN 2010 WITH THE GOAL OF BECOMING THE WORLD LEADER IN THE SAFE, CLEAN, AFFORDABLE PRODUCTION OF MEDICAL ISOTOPES. SINCE 2010, SHINE HAS AGGRESSIVELY PURSUED THE ESTABLISHMENT OF A DOMESTIC SOURCE OF HIGH SPECIFIC ACTIVITY MO-99 WITHOUT THE USE OF HEU TO END THE CHRONIC SHORTAGES US PATIENTS ARE EXPERIENCING.
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Fund SHINE Technologies to establish domestic production of molybdenum-99 medical isotopes without enriched uranium.
Reduces U.S. dependence on foreign medical isotope suppliers and addresses chronic shortages affecting patient care.
Strengthens domestic medical isotope supply chain; reduces reliance on Canadian and Australian imports.
Secures critical medical isotope supply domestically, reducing vulnerability to supply disruptions from geopolitical competitors.
Generated by award_classification v2.0.0 via claude-haiku-4-5-20251001 on 2026-05-15. Cost: $0.002209.
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier ASST_NON_DENA0004010_089.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.